- English (USA)
- English (UK)
- English (India)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Photocure (PHO)
Photocure stock price live, this page displays OL PHO stock exchange data. View the PHO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Photocure real time stock price chart below.
What Is the Photocure Stock Price Today?
The Photocure stock price today is 56.10.
What Is the Stock Symbol for Photocure?
The stock symbol for Photocure is "PHO."
What Stock Exchange Does Photocure Trade On?
Photocure is listed and trades on the Oslo stock exchange.
Is Photocure a Good Stock to Buy?
Determining whether Photocure—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PHO quote. (ISIN: NO0010000045)
What Is the Photocure Stock Price Today?
The Photocure stock price today is 56.10.
What Is the Stock Symbol for Photocure?
The stock symbol for Photocure is "PHO."
What Stock Exchange Does Photocure Trade On?
Photocure is listed and trades on the Oslo stock exchange.
Is Photocure a Good Stock to Buy?
Determining whether Photocure—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PHO quote. (ISIN: NO0010000045)
56.10
+0.70(+1.26%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
55.10
57.30
52 wk Range
47.00
65.60
PHO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
PHO is not included in our AI-picked strategies. See which stocks are.
Review Strategies
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
55.1057.30
52 wk Range
47.0065.60
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PHO Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Analysts Sentiment
Strong Buy
Price Target
82.50
Upside
+47.06%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Net income is expected to grow this year
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Neutral
Photocure Company Profile
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira; and a strategic agreement with Richard Wolf GmbH to develop and commercialize a 4K LED high-definition reusable blue light cystoscope based on Richard Wolf’s System blue technology. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. The company operates in the Nordic countries, Germany, France, Austria, the United Kingdom, the Benelux, Italy, rest of the Europe, Canada, and the United States. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
Photocure Earnings Call Summary for Q1/2025
- Q1 2025 revenue of 125M SEK missed forecast, causing 4.58% stock drop despite 7% YoY growth
- Net loss improved to 2.4M SEK from 7.9M SEK last year; EBITDA positive for 8th consecutive quarter
- US flexible cystoscopy kit sales declined 71%; North American revenue up 2%, European revenue up 11%
- Company maintains 11% product revenue growth guidance and expects further EBITDA improvement
- CEO highlights strong position in blue light cystoscopy; FDA reclassification efforts advancing
Last Updated: 2025-05-08, 08:46 a/m
Read Full TranscriptCompare PHO to Peers and Sector
Metrics to compare | PHO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPHOPeersSector | |
|---|---|---|---|---|
P/E Ratio | 689.4x | −0.1x | −0.5x | |
PEG Ratio | −12.41 | 0.02 | 0.00 | |
Price/Book | 3.1x | 2.1x | 2.6x | |
Price / LTM Sales | 2.8x | 1.2x | 3.1x | |
Upside (Analyst Target) | 48.9% | 52.5% | 45.7% | |
Fair Value Upside | Unlock | 9.2% | 5.7% | Unlock |
Analyst Ratings
2 Buy
0 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 82.50
(+47.06% Upside)
Earnings
Latest Release
May 08, 2025
EPS / Forecast
-0.09 / 0.185
Revenue / Forecast
125.30M / 133.35M
People Also Watch
FAQ
What Is the Photocure (PHO) Stock Price Today?
The Photocure stock price today is 56.10
What Stock Exchange Does Photocure Trade On?
Photocure is listed and trades on the Oslo Stock Exchange stock exchange.
What Is the Stock Symbol for Photocure?
The stock symbol for Photocure is "PHO."
What Is the Photocure Market Cap?
As of today, Photocure market cap is 1.49B.
What Is Photocure's Earnings Per Share (TTM)?
The Photocure EPS (TTM) is 0.08.
When Is the Next Photocure Earnings Date?
Photocure will release its next earnings report on Jul 30, 2025.
From a Technical Analysis Perspective, Is PHO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Photocure Stock Split?
Photocure has split 1 times.
How Many Employees Does Photocure Have?
Photocure has 100 employees.
What is the current trading status of Photocure (PHO)?
As of Jul 12, 2025, Photocure (PHO) is trading at a price of 56.10, with a previous close of 55.40. The stock has fluctuated within a day range of 55.10 to 57.30, while its 52-week range spans from 47.00 to 65.60.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.